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Abstract: Metabolic acidosis is a common complication in chronic kidney disease (CKD) patients,
and is associated with an accelerated decline in renal function. Oral bicarbonate therapy has been used
to counteract metabolic acidosis in CKD for decades. However, until recently, there have been very few
intervention studies testing the effectiveness of bicarbonate therapy at improving metabolic acidosis
or its consequences in patients with CKD. In this systematic review and meta-analysis, we aimed
to examine the outcomes of all published randomised controlled trials (RCTs) that investigated the
effect of oral bicarbonate therapy in adults with CKD. Ovid MEDLINE®, EMBASE® and Cochrane
Library were searched in mid-October 2018 for English literature, with no restrictions applied to
the publication status or date. Seven RCTs that recruited 815 participants met our inclusion criteria
after full text review. Oral bicarbonate supplementation resulted in a slightly higher estimated
glomerular filtration rate (eGFR) (mean difference 3.1 mL/min per 1.73 m2; 95% CI 1.3–4.9) and
serum bicarbonate levels (mean difference 3.4 mmol/L; 95% CI 1.9–4.9) at the end of follow-up (three
months to five years) compared to those given placebo or conventional CKD treatment. When limited
to studies reporting outcomes at one year, the positive effect of oral bicarbonate therapy on eGFR
was attenuated. There were no significant treatment effects in other parameters such as systolic
blood pressure (BP) and weight. These findings should be interpreted with caution and further trial
evidence is needed to establish the net overall benefit or harm of oral bicarbonate therapy in CKD.
Keywords: bicarbonate; acid-base balance; CKD
1. Introduction
More than 1.8 million people in England are known to have chronic kidney disease (CKD), while
another million of the population are thought to have the condition but are yet to be diagnosed [1,2].
CKD can significantly reduce quality and quantity of life and may lead to the need for renal replacement
therapy. Around 45,000 premature deaths are attributed to CKD annually in the United Kingdom [3].
Furthermore, the management of CKD places a substantial economic burden on healthcare systems
across the globe, and healthcare expenditure has been noted to be inversely proportional to renal
function [4]. The National Health Service (NHS) in England spent approximately £1.45 billion on CKD
in 2009–2010 [1]. Given the impact of CKD on quality of life and healthcare expenditure, interventions
that may slow the progression of CKD are of great importance.
Metabolic acidosis is frequently found in CKD patients, and becomes more common with
worsening renal function [4]. Metabolic acidosis has been operationalised as serum bicarbonate levels
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that are consistently below 22 mmol/L [4–6]. It is associated with other pathophysiological changes
including systemic inflammation, upregulation of parathyroid hormone receptors in osteoblasts and
increased activity of osteoclasts; which leads to accelerated bone resorption and osteopenia, reduction
of Na+-K+-ATPase activity in erythrocytes—resulting in impairment of myocardial contractility and
heart failure, and reduced respiratory reserve and exhaustion of body buffer systems, which increases
severity of acute intercurrent illnesses [4–10]. The degree of metabolic acidosis is directly associated
with glomerular filtration rate GFR, and is due to the failure of the kidneys to produce ammonia,
regenerate bicarbonate and excrete hydrogen ions [11]. Importantly, metabolic acidosis is associated
with an accelerated decline in renal function, an association that may be causal in nature [12].
As part of CKD patients’ care, oral alkali such as bicarbonates and citrates, base-producing fruits
and vegetables or low protein diets are commonly prescribed to avoid or correct metabolic acidosis.
Oral bicarbonate therapy has been used to counteract metabolic acidosis in CKD for decades. However,
until recently, there have been very few intervention studies testing the effectiveness of bicarbonate
therapy at improving metabolic acidosis, or its consequences in patients with CKD, and there are no
systematic reviews evaluating the effectiveness and safety of this approach. This is reflected by the
current guidelines, which are still unable to make an evidence-based recommendation regarding the
correction of mild-to-moderate acidosis in CKD [13]. To date, there is also no consensus on the optimal
range for serum bicarbonate in CKD patients. The paucity of clear guidelines results in variability
in clinical practice when prescribing oral bicarbonate therapy for patients with CKD and metabolic
acidosis [13].
In this systematic review and meta-analysis, we aimed to examine the outcomes of all published
randomised controlled trials (RCTs) that investigated the effect of oral bicarbonate therapy in
non-haemodialysis dependent adults with CKD.
2. Methods
2.1. Literature Search Strategy
The review protocol was registered in the PROSPERO database (Ref: CRD42018112908) [14].
Three databases (Ovid MEDLINE®, EMBASE® and Cochrane Library) were searched in mid-October
2018 for English literature, with no restrictions applied to the publication status or date. Grey literature
was not searched. The full search strategy is presented in Appendix A.
2.2. Inclusion and Exclusion Criteria
Our inclusion criteria were randomised controlled trials, availability of full text in English language,
all aetiologies and severities of CKD, comparison of bicarbonate therapy with placebo or standard care,
and any health-related outcome measures. Our exclusion criteria were children under the age of 18,
people receiving haemodialysis and the comparison of bicarbonate therapy with active treatment.
2.3. Study Selection
Two reviewers independently screened all titles and abstracts. The bibliographies of selected
articles were hand-searched for any other potentially relevant studies. Any uncertainties about study
eligibility were discussed between reviewers, and if necessary, with a third reviewer.
2.4. Data Extraction
A data extraction form was designed by adapting and customising the Cochrane collaboration’s
data collection form for intervention review—RCTs and non-RCTs [15]. Two independent assessors
performed the data extraction. Data discrepancies were resolved by discussion and consensus between
the two assessors.
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2.5. Risk of Bias
Risk of bias was evaluated using the Cochrane collaboration’s risk of bias tool [15]. Criteria assessed
included random sequence generation, allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selective reporting and other biases. Risk was
reported as low, high or unclear. Results from the assessment were subsequently tabulated using RevMan
5.3 (The Cochrane Collaboration, Copenhagen, Denmark) to generate a risk of bias graphic and summary
table [16].
2.6. Outcome Measures and Data Synthesis
The primary outcome measure of interest was the rate of change in estimated glomerular filtration
rate (eGFR). Secondary outcome measures were eGFR at the end of follow-up, mortality, blood pressure,
number of patients proceeding to renal replacement therapy and quality of life. Meta-analyses of these
and any other health-related outcome measures were performed when there were at least three trials
reporting the same outcome measure. The random effects model was used for continuous data and
forest plots generated using RevMan 5.3. Statistical heterogeneity in treatment effects was determined
using the I2 test.
2.7. Subgroup Analysis
Subgroup analyses were planned by mean study age, mean proportion of men and the duration
of the study.
3. Results
3.1. Study Selection
After deduplication, the search identified 307 potentially relevant articles, and 32 trials were
shortlisted after reading titles and abstracts (see Figure 1). Seven trials that recruited 815 participants
met the inclusion criteria after a full text review (see Table 1). Two trials were set in the USA and India,
respectively, with one trial each from Italy, South Korea and the UK.
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Table 1. Characteristics of included randomised controlled trial.
Study Location n Mean Age(Years) CKD Stage
Bicarbonate Level Entry
Criterion Intervention Comparator Duration Primary Outcome
Mathur et al.,
2006 [17] India 40 41
“Mild to moderate” CKD
(creatinine < 442
µmol/L). CKD stage not
specified
Not specified
Oral bicarbonate 1.2 mEq/kg
in 3 divided doses, titrated to
maintain serum bicarbonate in
range 22–26 mmol/L
Placebo 3 months Not specified
De Brito-
Ashurt et al.,
2009 [18]
UK 134 55 4 or 5 16 mmol/L < Bicarbonate <19 mmol/L
Oral bicarbonate 600 mg
3×/day, increased as needed
to maintain serum bicarbonate
> 23 mmol/L
Usual care 2 years
Decline in creatinine
clearance of
>3 mL/min/year
Mahajan et al.,
2010 [19] USA 120 51
2 with hypertension and
microalbuminuria Total CO2 > 24.5 mmol/L
Oral bicarbonate 0.5 mEq/kg
lean body weight Placebo 5 years eGFR decline rate
Jeong et al.,
2014 [20] South Korea 80 55 4 or 5 Total CO2 < 22 mmol/L
Oral bicarbonate 1 g 3×/day,
titrated to maintain serum
bicarbonate > 22 mmol/L
Usual care 12 months eGFR
Goraya et al.,
2014 [21] USA 108 54 3
22 mmol/L < Total CO2 <
24 mmol/L
Oral bicarbonate 0.3 mEq/Kg
lean body weight in three
divided doses
Usual care 3 years eGFR
Bellasi et al.,
2016 [22] Italy 145 65
3b or 4; in patients with
T2DM Bicarbonate < 24mmol/L
Oral bicarbonate 0.5 mEq/kg
twice daily, until serum
bicarbonate 24–28 mmol/L
Usual care 12 months Insulin resistance
Dubey et al.,
2018 [23] India 188 50 3 and 4 Bicarbonate < 22mmol/L
Oral bicarbonate titrated with
weekly monitoring Usual care 6 months
Mid-arm muscle
circumference
CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; CO2: Carbon dioxide; T2DM: Type 2 diabetes mellitus.
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3.2. Risk of Bias Analysis
Three RCTs described utilisation of adequate randomisation processes [18,21,22] to minimise
selection bias, while one study used patient’s identifying number [19], which was likely to have
increased the risk of bias (see Figures 2 and 3). Two RCTs applied allocation concealment by employing
a central randomisation process [22] or using opaque sequenced envelopes [23], but there was no
mention of allocation concealment in the other studies. All studies had a high risk of performance bias
due to the nature of the intervention, in which oral bicarbonate therapy was titrated and monitored to
achieve desired serum bicarbonate levels. Two studies used placebo as a comparator [17,19], which
might potentially reduce the risk of performance bias, but did not completely abolish it.
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Two RCTs reported blinding of their outcome assessors [18,23] while it was unclear in the rest
if this risk of bias was minimised or eliminated. All studies were deemed to have low attrition
bias as the dropout rate was less than 10% and accounted for in each study. The missing outcomes
were also thought to be insufficient to have a clinically relevant impact on the observed effect size.
Two studies recorded all expected outcomes using measurements and analysis methods that were
pre-specified [19,21], and therefore had a low reporting bias. Two RCTs were judged to have a high
risk of bias because outcome measures were detailed with an unconventional outcome measure
(decline in creatinine clearance) [18], and measurements (mean and 95% confidence interval (CI)) [23].
The remaining studies did not offer sufficient information to permit judgement about this criterion.
3.3. Outcomes
3.3.1. Serum Bicarbonate
All seven RCTs studied serum bicarbonate levels following the randomisation of study
participants (see Figure 4) [17–23]. Data from 707 patients were analysed; 57.9% were males and
their mean age ranged from 37.5 ± 17 years to 65.5 ± 11.4 years. Serum bicarbonate levels were higher
after oral bicarbonate therapy (mean difference 3.4 mmol/L; 95% CI 1.9–4.9) but the results were highly
heterogeneous (I2 = 97%).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 3 of 13 
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compared to placebo or conventional treatment for CKD (p = 0.19). 182 
Figure 4. Forest plot comparing the effects of oral bicarbonate therapy and control on serum bicarbonate
levels. Note: Boxes represent the mean difference between bicarbonate and control in individual trials.
The boxes are proportional to the weight of each study in the analysis and the lines represent their 95%
confidence interval (CI). The diamond represents the pooled mean difference, and its width represents its
95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: Variance of the effect size across studies;
Chi2: Weighted sum of squared differences between individual studies a d the pooled effect across
studies; df: Degrees of freedom; I2: Percentage of variation across studies that is due to heterogene ty;
Z: Test for overall effect across all studies.
3.3.2. eGFR and Serum Creatinine
Six RCTs [18–23] investigated eGFR after randomising patients to oral bicarbonate therapy or
placebo (see Figure 5). Data were not presented in a format that allowed the rate of change of eGFR
(the primary outcome measure) to be analysed, so eGFR at the end of follow-up was used. A total
of 667 patients were analysed; 57.7% w r males and their mean age ranged from 50.1 ± 11.6 years
to 65.5 ± 11.4 years. eGFR favoured bicarbonate therapy (mean difference 3.1 mL/min per 1.73 m2;
95% CI 1.3–4.9) but the analysis reveal d moderately igh heterogeneity (I2 = 68%).
Four studies measured serum creatinine at the end of their follow-up period (see Supplementary
Figure S1) [17,19,20,23]. Data from 361 patients were included; 61% were males and their mean age
ranged from 37.5 ± 17 years to 55.8 ± 12.7 years. Compared with placebo and standard care for CKD,
oral bicarbonate supplementation had non-significant effects on serum creatinine (p = 0.09).
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Figure 5. Forest plots comparing the effects of oral bicarbonate therapy and control on eGFR and
serum creatinine levels. Note: Boxes represent the mean difference between bicarbonate and control
in individual trials. The boxes are proportional to the weight of each study in the analysis and the
lines represent their 95% confidence interval (CI). The diamond represents the pooled mean difference,
and its width represents its 95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: Variance of
the effect size across tudies; Chi2: Weighted sum of squared differences b tw e individu l studies
and the pooled effect across stud es; df: Degrees of freedom; I2: Perc ntag of variation across studies
that is due to heterogeneity; Z: Test for overall effect across all studies.
3.3.3. Systolic Blood Pressure
Six studies recorded systolic blood pressure (BP) as an outcome measure (see Figure 6) [17–19,21–23].
A total of 635 patients were included; 57.3% were males and their mean age ranged from 37.5 ± 17 years
to 65.5 ± 11.4 years. Oral bicarbonate therapy had uncertain effects on systolic BP when compared to
placebo or conventional treatment for CKD (p = 0.19).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 4 of 13 
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3.3.5. Other Outcomes 206 
The rate of change of eGFR was intended as a primary outcome, but data from multiple trials 207 
were not presented in a format that enabled this parameter to be analysed, so eGFR at the end of 208 
follow-up was used. Other listed outcomes that were not available included mortality rate, number 209 
of patients proceeding to renal replacement therapy and quality of life. 210 
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Figure 6. Forest plot comparing the effects of oral bicarbonate therapy and control on systolic blood
pressure. Note: Boxes represent the mean difference between bicarbonate and control in individual
trials. The boxes are proportional to the weight of each study in the analysis and the lines represent
their 95% confidence interval (CI). The diamond represents the pooled mean difference, and its width
represents its 95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: Variance of the effect size
across studies; Chi2: Weighted sum of squared differences between individual studies and the pooled
effect across studies; df: De rees of freedom; I2: Percentage of variation across stu ies that is due to
het rogeneity; Z: Test for overall effect across all studies.
3.3.4. Weight
Five RCTs reported the weight of their patients at the conclusion of their studies (see
Figure 7) [17,20–23]. 507 patients were analysed; 69.3% were males and their mean age ranged from
37.5 ± 17 years to 65.5 ± 11.4 years. The effects of oral bicarbonate therapy on weight of CKD patients are
uncertain (p = 0.3) and the results ar highly heterog neous (I2 = 87%).
J. Clin. Med. 2019, 8, 208 8 of 12
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 4 of 13 
 
 183 
Figure 6. Forest plot comparing the effects of oral bicarbonate therapy and control on systolic blood 184 
pressure. Note: Boxes represent the mean difference between bicarbonate and control in individual 185 
trials. The boxes are proportional to the weight of each study in the analysis and the lines represent 186 
their 95% confidence interval (CI). The diamond represents the pooled mean difference, and its width 187 
represents its 95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: Variance of the effect 188 
size across studies; Chi2: Weighted sum of squared differences between individual studies and the 189 
pooled effect across studies; df: Degrees of freedom; I2: Percentage of variation across studies that is 190 
due to heterogeneity; Z: Test for overall effect across all studies. 191 
3.3.4. Weight 192 
Five RCTs reported the weight of their patients at the conclusion of their studies (see Figure 7) 193 
[17,20–23]. 507 patients were analysed; 69.3% were males and their mean age ranged from 37.5 ± 17 194 
years to 65.5 ± 11.4 years. The effects of oral bicarbonate therapy on weight of CKD patients are 195 
uncertain (p = 0.3) and the results are highly heterogeneous (I2 = 87%). 196 
 197 
Figure 7. Forest plot comparing the effects of oral bicarbonate therapy and control on weight. Note: 198 
Boxes represent the mean difference between bicarbonate and control in individual trials. The boxes 199 
are proportional to the weight of each study in the analysis and the lines represent their 95% 200 
confidence interval (CI). The diamond represents the pooled mean difference, and its width 201 
represents its 95% CI. SD: Standard deviation; CI: Confidence interval; Tau2: Variance of the effect 202 
size across studies; Chi2: Weighted sum of squared differences between individual studies and the 203 
pooled effect across studies; df: Degrees of freedom; I2: Percentage of variation across studies that is 204 
due to heterogeneity; Z: Test for overall effect across all studies. 205 
3.3.5. Other Outcomes 206 
The rate of change of eGFR was intended as a primary outcome, but data from multiple trials 207 
were not presented in a format that enabled this parameter to be analysed, so eGFR at the end of 208 
follow-up was used. Other listed outcomes that were not available included mortality rate, number 209 
of patients proceeding to renal replacement therapy and quality of life. 210 
3.4. Subgroup Analyses 211 
Subgroup analyses were performed by the duration of the study, thereby eliminating one source 212 
of heterogeneity. These analyses were only possible for eGFR and serum bicarbonate at one year 213 
follow-up (see Supplementary Figures S2 and S3), as there were too few studies or insufficient data 214 
in other outcome measures to allow for meaningful analysis. 215 
Three studies investigated eGFR and serum bicarbonate levels at one year after the 216 
randomisation of patients to oral bicarbonate therapy or placebo treatment [18,20,22]. Of the 347 217 
patients that were analysed; 55.4% were males and their mean age ranged from 53.3 ± 13.5 years to 218 
65.5 ± 11.4 years. The effects of bicarbonate therapy on eGFR were non-significant when the duration 219 
Figure 7. Forest plot comparing the effects of oral bicarbonate therapy and control on weight. Note:
Boxes represent the mean difference between bicarbonate and control in individual trials. The boxes
are proportional to the weight of each study in the analysis and the lines represent their 95% confidence
interval (CI). The diamond represents the pooled mean difference, and its width represents its 95% CI.
SD: Standard deviation; CI: Confidence interval; Tau2: Variance of the effect size across studies; Chi2:
Weighted sum of squared differences between individual studies and the pooled effect across studies;
df: Degrees of freedom; I2: Perc ntage of variation across studi that is due to heterogeneity; Z: Test
for ov rall effect across all studies.
3.3.5. Other Outcomes
The rate of change of eGFR was intended as a primary outcome, but data from multiple trials
were not presented in a format that enabled this parameter to be analysed, so eGFR at the end of
follow-up was used. Other listed outcomes that were not available included mortality rate, number of
patients proceeding to renal replacement therapy and quality of life.
3.4. Subgroup Analyses
Subgroup analyses were performed by the duration of the study, thereby eliminating one source
of heteroge eity. These analyses were only possible for eGFR and serum bicarbonate at one year
follow-up (see Supplementary Figures S2 and S3), as there were too few studies or insufficient data in
other outcome measures to allow for meaningful analysis.
Three studies investigated eGFR and serum bicarbonate levels at one year after the randomisation
of patients to oral bicarbonate therapy or placebo treatment [18,20,22]. Of the 347 patients that were
analysed; 55.4% were males and their ean age ranged from 53.3 ± 13.5 years to 65.5 ± 11.4 years.
he ffects of bicarbonate therapy on eGFR were non-significant wh n the duration of the study was
stand rdised at one year (p = 0.19). The heterogeneity f tre tment sults was lower than other
analyses (I2 = 46%). Serum bicarbonat at one year was high r after or l bicarbonate therapy (mean
difference 3.2 mmol/L, 95% CI 2.0–4.3), but there was still significant heterogeneity (I2 = 66%).
4. Discussion
4.1. Outcomes
Oral bicarbonate supplementation resulted in a slightly higher eGFR at the end of follow up (three
months to five years) compared to those given placebo or conventional CKD treatment. Bicarbonate
therapy also improved serum bicarbonate levels by an average of 3.2 mmol/L compared to the
control arm, but we did not find any significant treatment effects in other parameters such as systolic
BP and weight.
These findings should be interpreted with caution due to a high level of heterogeneity between
studies. The heterogeneity probably reflects the marked differences across trials, ranging from
population demographics to dosing regimen and length of follow-up. Furthermore, the mean age of
trial participants was remarkably low despite the increased prevalence of CKD in older people [1,2].
All but one trial recruited patients with a mean age below 56 years. Although most epidemiological
studies observed that CKD was more common in women, all seven RCTs in this review enrolled
more men than women [24]. This suggests that there may be a degree of selection bias in trial
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recruitment that may limit the generalisation of results in clinical practice. Some trials recruited
atypical populations, e.g., those with stage 2 CKD with albuminuria due to hypertension [19] or those
with CKD of unknown aetiology in India [17]. It is not clear that the observed treatment effects would
be seen in more typical patients with CKD. Patients’ dietary intakes were not clearly accounted for,
and this might have influenced the serum bicarbonate levels, as acid- and base-producing diets are
known to skew bicarbonate levels. Patients also had various co-morbidities such as cardiovascular
diseases and type 2 diabetes mellitus, but this confounding factor might be difficult to avoid when
recruiting CKD patients, as most patients have at least one, if not more, co-morbidities.
Almost all trials included in this analysis were open-label, and it is known that unmasked trial
designs tend to overestimate the treatment effect size compared to placebo. Several trials adopted
a ‘treat to target’ approach for bicarbonate, in which doses were escalated in the intervention arm to
try and reach a pre-defined bicarbonate level. Such approaches again tend to magnify treatment effects
compared to the comparison of bicarbonate at a fixed dose with controls, although it can be argued
that such an approach better approximates clinical practice.
Another likely confounding factor is the duration of study. When limited to studies reporting
outcomes at one year of follow-up, the positive effect of oral bicarbonate therapy on eGFR was
attenuated and eGFR did not differ significantly between those on bicarbonate supplementation and
placebo. All trials also recruited patients with a wide range of baseline bicarbonate levels (16 to
24 mmol/L), and this may have had an influence on the observed response to treatment, such that
studies that began with lower baseline bicarbonate levels might have witnessed a larger treatment
effect size.
Our results revealed that a modest total of 815 participants worldwide had been recruited into
seven RCTs of bicarbonate therapy. It is highly likely that future studies will influence the results of the
meta-analysis. The authors are aware of four further relevant RCTs that have published their protocols
but are yet to report their results—BiCARB [13], UBI [25], SoBic [26] and BASE [27]. Their planned
recruitment figures should more than double the number of participants in trials of bicarbonate
treatment in CKD to date, as well as address current weaknesses in the evidence base, such as a lack of
older people and data on physical function and quality of life.
4.2. Potential Adverse Effects of Bicarbonate Oral Therapy
As with most medications, oral bicarbonate therapy comes with its own adverse effects and
cautions. Sodium bicarbonate tablets are awkward to take, especially for older people with impaired
swallowing and polypharmacy; the tablets are large and several tablets are usually required to be
taken at one time or in a day [13]. The British National Formulary (BNF) listed abdominal discomfort
and bloating as recognised side effects, which may lead to compliance issues in patients [13]. 600 mg
sodium bicarbonate tablets taken three times daily cost the NHS £190 per patient per year, despite
a lack of robust evidence supporting the efficacy of this treatment.
Sodium bicarbonate tablets also contain 6 mmol of sodium in every 500 mg, which could
contribute to hypertension and fluid overload if not monitored closely, especially in a population with
impaired renal clearance [24]. This finding is corroborated by observational studies, which suggested
that elevated serum bicarbonate levels were associated with an increased risk of heart failure in CKD
patients [28]. It is therefore reassuring that this meta-analysis did not demonstrate any worsening of
systolic blood pressure with bicarbonate therapy.
The targeted serum bicarbonate level, dose and time of initiation are yet to be determined. Despite
new evidence suggesting the range of potential benefits, overtreatment with oral alkali therapy may
result in metabolic alkalosis, which is also associated with poor outcomes in patients with CKD [11].
An alkaline pH has also been shown to augment vascular calcification in animal models [11]. As arterial
elasticity declines with age and older people are more likely to have CKD, caution has to be exercised
when considering oral bicarbonate therapy.
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4.3. Strengths and Limitations
To our knowledge, this is the first synthesis of trials investigating the effects of bicarbonate therapy.
All fully published trials were included and we undertook meta-analysis where possible. However,
there was substantial heterogeneity in all included studies. The seven RCTs had important differences
in various parameters including population demographics, intervention regimes, outcome measures
and duration of study. Additionally, studies were often at high risk of bias but poorer quality studies
could not be excluded due to the limited number of published RCTs that suited our inclusion criteria.
5. Conclusions
Bicarbonate supplementation modestly improved eGFR and serum bicarbonate levels compared to
placebo or conventional CKD management. Evidence of improvement in other health-related outcome
measures was lacking. These findings should be interpreted with caution due to high heterogeneity and
risk of bias in studies. Further trial evidence is needed to establish the net overall benefit or harm of oral
bicarbonate therapy in CKD, and to define the target groups most likely to benefit from treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/2/208/s1,
Supplementary Figure S1. Forest plot comparing the effects of oral bicarbonate therapy and control on serum
creatinine levels. Supplementary Figure S2. Forest plot comparing the effects of oral bicarbonate therapy and
control on eGFR at one year. Supplementary Figure S3. Forest plot comparing the effects of oral bicarbonate
therapy and control on serum bicarbonate levels at one year.
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Appendix A Search Strategy
Table A1. Search strategy in MEDLINE.
1 exp Bicarbonates [MeSH] or exp Sodium Bicarbonate [MeSH] or bicarbonates [tiab] 24,367
2 Chronic Kidney Disease or CKD [mp] or exp Renal Insufficiency, Chronic [MESH] or orChronic Renal Insufficiency [tiab] 127,737
3
(exp Bicarbonates [MeSH] or exp Sodium Bicarbonate [MESH] or bicarbonates [tiab]) and
(Chronic Kidney Disease or CKD [mp] or exp Renal Insufficiency, Chronic [MESH] or or
Chronic Renal Insufficiency [tiab])
812
4 Limit 3 to RCT and English language 76
exp: Explode; MeSH: Medical Subject Headings; tiab: Title or abstract; mp: Keyword; RCT: Randomised
controlled trials.
Table A2. Search strategy in EMBASE.
1 exp Bicarbonate [MeSH] or Bicarbonate.mp 69,535
2
exp Chronic Kidney Failure [MeSH] or (chronic kidney disease or chronic kidney failure or
chronic kidney insufficiency or chronic renal disease or chronic renal failure or chronic
renal insufficiency).mp
116,647
3
(exp Bicarbonate [MeSH] or Bicarbonate.mp) and (exp Chronic Kidney Failure [MeSH] or
(chronic kidney disease or chronic kidney failure or chronic kidney insufficiency or
chronic renal disease or chronic renal failure or chronic renal insufficiency).mp)
2323
4 Limit 3 to English language and exclude Medline journals and RCT 3
exp: Explode; MeSH: Medical Subject Headings; mp: Keyword; RCT: Randomised controlled trials.
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Table A3. Search strategy in Cochrane.
1 MeSH descriptor. [Bicarbonates] explode all trees 1201
2 MeSH descriptor: [Sodium Bicarbonate] explode all trees 610
3 #1 or #2 or (Bicarbonate *) 3123
4 MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees 5705
5 Chronic kidney disease or chronic kidney failure or chronic kidney insufficiency orchronic renal disease or chronic renal failure or chronic renal insufficiency 13,858
6 #4 or #5 13,524
7 #3 and #6 in Trials 304
MeSH: Medical Subject Headings; * (truncation symbol) is used to search for multiple variants of a word all at once.
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